Abstract:ObjectiveTo investigate the possible influence of long-term antiviral therapy with entecavir on renal function in patients with chronic hepatitis B (CHB) and the sensitive indicators for early identification of renal injury. MethodsA cross-sectional real-world study was conducted for the clinical data of 125 CHB patients treated with entecavir for more than 1 year (treatment group) and 44 patients with chronic HBV infection who did not receive antiviral therapy (control group), including the changes in serum creatinine (SCr), estimated glomerular filtration rate (eGFR), and the levels of urinary α1 microglobulin (α1-MG), β2 microglobulin (β2 -MG), and N-acetyl-β-D-glucosaminidase (NAG). The chi-square test or the Fisher’s exact test was used for comparison of categorical data between groups. The independent-samples t test was used for comparison of normally distributed continuous data between groups, and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between groups. The Logistic regression analysis was used to investigate independent influencing factors for abnormal urinary α1-MG, β2-MG, and NAG in the treatment group. Results There were no significant differences in SCr and eGFR between the treatment group and the control group (t=0.999 and -1259, P＞0.05), and both indices were within the normal range in these two groups. The treatment group had significantly higher abnormal rates of urinary α1-MG and β2-MG than the control group (47.2%/42.4% vs 13.6%/136%, χ2=15693 and 12.567, both P＜0.001), and compared with the control group, the treatment group had a significantly higher proportion of patients with α1-MG or β2-MG ＞2×upper limit of normal (18.4%/21.6% vs 2.3%/4.5%, both P＜005); however, there were no significant differences between the treatment group and the control group in the abnormal rate of urinary NAG (8.0% vs 6.8%, P＞0.05) and the proportion of patients with urinary NAG ＞2×upper limit of normal (88% vs 6.8%, P＞0.05). Compared with the control group, the treatment group had a significantly higher proportion of patients with abnormalities in two or more indicators for renal tubular injury (33.6% vs 11.4%, χ2=8.519, P＜0.05), while there was no significant difference between the two groups in the proportion of patients with abnormalities in one indicator (16.0% vs 11.4%, P＞0.05). ConclusionLong-term treatment of CHB with entecavir may be associated with the risk of renal tubular dysfunction, and abnormalities in more than two indicators for renal injury may help to identify renal tubular dysfunction in patients, so as to adjust related treatment in time.

Effect of Entecavir on the Intestinal Microflora in Patients with Chronic Hepatitis B: A Controlled Cross-Sectional and Longitudinal Real-World Study

Effect of Additional Clostridium butyricum on the Intestinal Flora of Chronic Hepatitis B Patients Treated with Entecavir

Correlation Between Serum Entecavir Concentration And Virological Response In Patients With Chronic Type B Hepatitis

Entecavir maleate versus entecavir in Chinese chronic hepatitis B predominantly genotype B or C: Results at week 144.

Changes of Fecal Bifidobacterium Species in Adult Patients with Hepatitis B Virus-Induced Chronic Liver Disease

Association Between Hepatic Steatosis And Entecavir Treatment Failure In Chinese Patients With Chronic Hepatitis B

Outcomes of Long-term Treatment of Chronic HBV Infection With Entecavir or Other Agents From a Randomized Trial in 24 Countries.

Intestinal Microbiota Was Assessed in Cirrhotic Patients with Hepatitis B Virus Infection

Efficacy and safety of entecavir treatment in a heterogeneous CHB population from a ‘real-world’ clinical practice setting in China.

Effect of Entecavir on CD4+ T-cell Subpopulations in Patients with Chronic Hepatitis B.

A randomized, double-blind, double-dummy, controlled, multicenter study of entecavir maleate versus entecavir for treatment of HBeAg-negative chronic hepatitis B: results at week 48

Effects of Entecavir on Peripheral Blood Lymphocyte Profiles in Chronic Hepatitis B Patients with Suboptimal Responses to Adefovir

Clinical efficacy of traditional Chinese medicine combined with entecavir in chronic hepatitis B patients

Gut microbiota dysbiosis associated with plasma levels of Interferon-gamma and viral load in patients with acute hepatitis E infection

Clinical Efficacy and Incidence of Adverse Reactions of Entecavir Combined with Long-Acting Interferon in Treating Hepatitis B

Clinical effectiveness of combined Bifidobacterium live bacteria preparation and entecavir therapy in the management of Hepatitis B cirrhosis

Influence of Long-Term Use of Entecavir on Renal Tubular Function in Patients with Chronic Hepatitis B

Decline of Hepatitis B Virus Load Correlate with Increase of Th1/Th2 Immunity in Chronic Hepatitis B Patients During Long-Term Treatment with Entecavir

Incidence and Resolution of Steatohepatitis in Patients Receiving Entecavir for Chronic Hepatitis B

Study of Entecavir in Cirrhosis Due to Chronic Hepatitis B

Virological, Serological and Biochemical Outcomes Through 3 Years of Entecavir Treatment in Nucleoside-Naive Chinese Chronic Hepatitis B Patients